TRAW
Traws Pharma Inc
NASDAQ: TRAW · HEALTHCARE · BIOTECHNOLOGY
$0.56
+6.17% today
Updated 2026-09-11
Market cap
$8.33M
P/E ratio
—
P/S ratio
2.98x
EPS (TTM)
$-1.74
Dividend yield
—
52W range
$0 – $3
Volume
0.1M
WallStSmart proprietary scores
22
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+3.8
Quality
D3.0
Profitability
D5.0
Valuation
C+4/9
Piotroski F-Score
Moderate
-90.0
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →251 stocks currently score above 75
Price targets
Analyst target
$1.00
+77.21%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy0 Buy2 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
Insufficient data
Risks
- Altman Z -90.04 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.50M
- Revenue declining -100.00% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $226000.00 | $226000.00 | $226000.00 | $2.79M | $0.00 |
| Net income | $-18.96M | $-18.95M | $-54.67M | $9.17M | $-3.05M |
| EPS | — | — | — | — | $-1.74 |
| Free cash flow | $-16.29M | $-17.95M | $-29.79M | $-20.77M | $-7.50M |
| Profit margin | -8,391.15% | -8,384.07% | -24,192.04% | 328.67% | — |
Peer comparison
Smart narrative
Traws Pharma Inc trades at $0.56. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of -90.04, it sits in the distress.
Frequently asked questions
What is Traws Pharma Inc's stock price?
Traws Pharma Inc (TRAW) trades at $0.56, on a P/S of 3.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Traws Pharma Inc overvalued?
Traws Pharma Inc carries a Smart Value Score of 22/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Traws Pharma Inc (TRAW)?
The 12-month analyst consensus target is $1.00, about 77.2% above the current $0.56. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Traws Pharma Inc's Altman Z-Score is -90.04, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.98x
ROE-5,639.00%
Beta1.56
50D MA$0.61
200D MA$1.45
Shares out0.02B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—